Abstract:

Objective To explore the therapeutic effect of doubling the first dose of batroxobin in the treatment of sudden sensorineural hearing loss with reduced frequency. Methods A total of 96 patients diagnosed with sudden sensorineural hearing loss， who received treatment at the Department of Otolaryngology at the Second Affiliated Hospital of Guizhou Medical University between August 2022 and October 2024， were included in the study. Using the random number table method， the patients were assigned to two groups， an observation group and a control group， each comprising 48 cases. The control group was treated with Ginkgo biloba extract， methylprednisolone tablets， and a first dose of 10 BU of batroxobin， while the observation group was treated with Ginkgo biloba extract， methylprednisolone tablets， and a first dose of 20 BU of batroxobin. After one cycle of treatment， compare the pure tone hearing threshold， hemorheological indicators， coagulation function indicators， efficacy， and adverse reactions between the two groups. Follow up for 6 months and record the recurrence outcome. Results After treatment， the pure tone hearing threshold of both groups decreased， and the observation group was lower than the control group （P < 0.05）. After treatment， the effective rates of the observation group and the control group were 77.08% and 54.17%， respectively， and the whole blood low shear viscosity was （18.27 ± 1.63） （20.29 ± 1.41） mPa·s， the whole blood shear viscosity was （5.58 ± 0.64）， （6.01 ± 0.69） mPa·s， the whole blood high shear viscosity is （4.26 ± 0.38）， （4.54 ± 0.31） mPa·s， the plasma viscosity is （1.52 ± 0.26）， （1.71 ± 0.34） mPa·s， the red blood cell aggregation index is （0.60 ± 0.21）， （0.52 ± 0.17）， the red blood cell deformation index was （5.73 ± 0.61）， （6.20 ± 0.64）， and the fibrinogen （FIB） is （0.72 ± 0.18）. 0.95 ± 0.13） g/L， thrombin time （TT） were （23.51 ± 2.08） and （21.76 ± 2.13） s， prothrombin time （PT） were （12.71 ± 0.63） and （12.05 ± 0.65） s， respectively， and activated partial thromboplastin time （APTT） were （28.32 ± 3.07） and （29.51 ± 2.24） s， respectively， with the observation group showing more significant changes （P < 0.05）. The recurrence rate of the observation group was lower than that of the control group （P < 0.05）. Conclusion Doubling the first dose of batroxobin can help alleviate the symptoms of hearing impairment， improve inner ear microcirculation， and enhance treatment efficacy in patients with total frequency decline type sudden deafness.

Key words: batroxobin, double the first dose, full frequency descent type, sudden deafness